Phoenix PharmaLabs, a privately held, pre-clinical stage drug development company based in Woods Cross, Utah, is dedicated to providing potent pain therapies without the risks of addiction and serious side effects. Their mission is to bring safe and effective pain relief options to the market. Their lead drug candidate, PPL-138, offers a groundbreaking solution for both acute and chronic pain, with preclinical validation showing it to be 100 times more potent than morphine, while also having a low risk of abuse or addiction and no respiratory depression.

Another drug candidate, PPL-103, shows promising potential for treating addiction and pain, with reduced side effects. Phoenix PharmaLabs is actively advancing PPL-138 into Phase I human clinical trials, with more than $23 million raised to date from grants, equity investments, and in-kind investments. Both of their drug candidates have the potential to capture a significant portion of the $30 billion opioid therapeutics market.

With a portfolio of drugs that address the unmet medical need for safe and comprehensive pain relief, Phoenix PharmaLabs continues to seek business and investment relationships to further their research and development efforts. Contact them to learn more about their innovative approach to pain management